863 related articles for article (PubMed ID: 31867006)
1. Harnessing NK Cells for Cancer Treatment.
Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E
Front Immunol; 2019; 10():2836. PubMed ID: 31867006
[TBL] [Abstract][Full Text] [Related]
2. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
Kim N; Kim HS
Front Immunol; 2018; 9():2041. PubMed ID: 30250471
[TBL] [Abstract][Full Text] [Related]
3. The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
Sun H; Sun C
Front Immunol; 2019; 10():2354. PubMed ID: 31681269
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
5. Natural killer cells in cancer biology and therapy.
Wu SY; Fu T; Jiang YZ; Shao ZM
Mol Cancer; 2020 Aug; 19(1):120. PubMed ID: 32762681
[TBL] [Abstract][Full Text] [Related]
6. PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.
Pesce S; Greppi M; Grossi F; Del Zotto G; Moretta L; Sivori S; Genova C; Marcenaro E
Front Immunol; 2019; 10():1242. PubMed ID: 31214193
[TBL] [Abstract][Full Text] [Related]
7. Harnessing NK cells for cancer immunotherapy: immune checkpoint receptors and chimeric antigen receptors.
Kim N; Lee DH; Choi WS; Yi E; Kim H; Kim JM; Jin HS; Kim HS
BMB Rep; 2021 Jan; 54(1):44-58. PubMed ID: 33298244
[TBL] [Abstract][Full Text] [Related]
8. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
9. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C; Liu Y
Front Immunol; 2020; 11():1295. PubMed ID: 32714324
[TBL] [Abstract][Full Text] [Related]
10. Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes.
Pesce S; Trabanelli S; Di Vito C; Greppi M; Obino V; Guolo F; Minetto P; Bozzo M; Calvi M; Zaghi E; Candiani S; Lemoli RM; Jandus C; Mavilio D; Marcenaro E
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255582
[TBL] [Abstract][Full Text] [Related]
11. Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy.
Alfarra H; Weir J; Grieve S; Reiman T
Front Immunol; 2020; 11():575609. PubMed ID: 33304346
[TBL] [Abstract][Full Text] [Related]
12. Multiple Defects of Natural Killer Cells in Cancer Patients: Anarchy, Dysregulated Systemic Immunity, and Immunosuppression in Metastatic Cancer.
Jewett A; Kos J; Kaur K; Turnsek TL; Breznik B; Senjor E; Wong P; Nguyen KY; Ko MW
Crit Rev Immunol; 2020; 40(2):93-133. PubMed ID: 32749091
[TBL] [Abstract][Full Text] [Related]
13. NK Cell Dysfunction and Checkpoint Immunotherapy.
Bi J; Tian Z
Front Immunol; 2019; 10():1999. PubMed ID: 31552017
[TBL] [Abstract][Full Text] [Related]
14. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
15. Human NK cells: From surface receptors to clinical applications.
Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Human NK Cells in Tumor Therapy.
Vacca P; Pietra G; Tumino N; Munari E; Mingari MC; Moretta L
Front Immunol; 2019; 10():3013. PubMed ID: 32010130
[TBL] [Abstract][Full Text] [Related]
17. Natural killer cells as a promising therapeutic target for cancer immunotherapy.
Kim N; Lee HH; Lee HJ; Choi WS; Lee J; Kim HS
Arch Pharm Res; 2019 Jul; 42(7):591-606. PubMed ID: 30895524
[TBL] [Abstract][Full Text] [Related]
18. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
Ben-Shmuel A; Biber G; Barda-Saad M
Front Immunol; 2020; 11():275. PubMed ID: 32153582
[TBL] [Abstract][Full Text] [Related]
19. The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy.
Souza-Fonseca-Guimaraes F; Cursons J; Huntington ND
Trends Immunol; 2019 Feb; 40(2):142-158. PubMed ID: 30639050
[TBL] [Abstract][Full Text] [Related]
20. Back to the Future: Spatiotemporal Determinants of NK Cell Antitumor Function.
Li JH; O'Sullivan TE
Front Immunol; 2021; 12():816658. PubMed ID: 35082797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
